News & Press: Latest News

MDMA Submits Comments to CDC on Acute & Chronic Pain Management and the Role of MedTech Therapies

Tuesday, June 16, 2020  
Share |

MDMA Submits Comments to CDC on Acute & Chronic Pain Management and the Role of MedTech Therapies

 

The Medical Device Manufacturers Association (MDMA) submitted comments today to the Centers for Disease Control (CDC) in response to their request for comment on the management of acute and chronic pain. MDMA applauded the agency for seeking the perspectives and experiences of those confronting pain and pain management, and their desire to better understand stakeholders’ values and preferences related to these important issues.  MDMA noted that there are hundreds of Food and Drug Administration (FDA) approved or cleared medical devices in the marketplace that can treat acute and chronic pain, and we urged the CDC to update guidelines to reflect the appropriate role of opioid-sparing medical devices in managing patients’ pain. Additionally, we reaffirmed our support of the 2019 HHS Pain Management Best Practices Inter-Agency Task Force (Task Force) final report and encouraged CDC to incorporate report findings and recommendations in the next iteration of CDC’s guideline for prescribing opioids. You can view our comments by CLICKING HERE.